Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gletimbetasin
- Development stage
- Phase 1
- Lead developer
- Northland Biotech
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Gletimbetasin (NL005) is a recombinant human thymosin beta 4 (Tβ4) protein being developed by Beijing Northland Biotech for the treatment of cardiovascular and respiratory conditions. Comprised of 44 amino acids, it acts as an actin-sequestering protein and modulator of thymosin beta 4. In the context of acute myocardial infarction, it is designed to improve heart function, enhance collateral circulation, and mitigate myocardial reperfusion injury. Preclinical studies have demonstrated its potential to improve cardiac configuration and safety. It is currently being evaluated in clinical trials for acute myocardial infarction and has been studied in healthy volunteers to assess safety, tolerability, and pharmacokinetics.
- Brand names
- Gletimbetasin
- Other names
- recombinant human thymosin beta4rh-Tβ4
02
Targets
Actin filament proteinsTMSB4X (Thymosin beta-4 X-linked)
Beyond the preview
Go deeper on gletimbetasin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gletimbetasin.